557results about How to "Decrease in level" patented technology

An electrosurgical generator has an output power control system that causes the impedance of tissue to rise and fall in a cyclic pattern until the tissue is desiccated. The advantage of the power control system is that thermal spread and charring are reduced. In addition, the power control system offers improved performance for electrosurgical vessel sealing and tissue welding. The output power is applied cyclically by a control system with tissue impedance feedback. The impedance of the tissue follows the cyclic pattern of the output power several times, depending on the state of the tissue, until the tissue becomes fully desiccated. High power is applied to cause the tissue to reach a high impedance, and then the power is reduced to allow the impedance to fall. Thermal energy is allowed to dissipate during the low power cycle. The control system is adaptive to tissue in the sense that output power is modulated in response to the impedance of the tissue.

A series of nips (200, 202, 204, 412, 414) formed by intermeshing grooves (22, 24, 26, 28) provides for a higher degree of stretch, particularly for lightweight webs (100) by stretching in stages in multiple grooved nips. The ability to adjust the degree of stretch at each nip can provide a high degree and variability of stretch with reduced web damage compared to a single step application of the same stretch. Improvements to the manufacture of lightweight components of personal care products such as diaper backing components are obtained.

The invention relates to systems and methods for local renal delivery of agents to subjects that are at risk for congestive heart failure and other conditions. The invention encompasses devices for renal drug delivery and methods of use.

The present invention provides transgenic plants with reduced levels of saturated fatty acids in the seed oil and methods of making these plants. The transgenic plants developed through this method contain reduced levels of saturated fatty acids in seed oil due to expression of a prokaryotic delta-9 desaturase enzyme (i.e. an enzyme that introduces cis double bonds at the delta-9 position of saturated fatty acids) operably linked with an endoplasmic reticulum retention and retrieval signal sequence. One example of the invention is a plant expressing a heterologous delta-9 desaturase enzyme from cyanobacterium Anacystis nidulans, which converts lipid-bound 16:0 and 18:0 fatty acids into corresponding 16:1 and 18:1, in operative linkage with a KKSS (SEQ ID NO:5) endoplasmic reticulum retention and retrieval signal sequence.

The invention in its various embodiments provides a microcapsule product with reduced levels of formaldehyde. Formaldehyde levels are reduced by the inclusion of a formaldehyde scavenger. The microcapsules provided are well suited for rinse-off applications associated with personal care and cleaning products

In one aspect the present disclosure provides a method of rehabilitating a person who has suffered central nervous system damage including the steps of providing exercise equipment capable of exercising a person's limbs, providing functional electrical stimulation to the person's limbs to be exercised in order to operate the exercise equipment, increasing the level of functional electrical stimulation; decreasing a resistance provided by the exercise equipment or providing assistance to maintain an acceptable speed of the exercise equipment as the person's muscles tire; finally completely removing functional electrical stimulation to the person's limbs and providing assistance to maintain an acceptable speed of the exercise equipment; and continuing passive exercise of the person's limbs for a period of time greater than two minutes. Also provided are apparatuses to carry out the method.

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.

Diamond bonded constructions comprise a diamond body attached to a substrate, wherein the body includes a first diamond bonded volume, and a second diamond bonded volume attached thereto. The second volume may be provided in the form of a powder or a presintered mass prior to attachment, and the first volume may be provided in the form of presintered pieces when combined with the second volume. The first volume diamond volume content is greater than about 94 percent, and is the same or greater than that of the second volume. The first volume is sintered during a first HPHT process, and the second volume is sintered and / or attached to the first volume during a second HPHT process. The first HPHT pressure is greater than the second HPHT pressure. The substrate is not an infiltration substrate used to form the first diamond volume. The diamond body may be thermally stable.

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

A drive apparatus for driving two motors by PWM control of respective switching elements connected to the motors, whereby respective control signals are applied to the switching elements such that each commencement of a transition of one of the switching elements from the non-conducting to the conducting state coincides with the termination of a transition of the other switching element from the conducting to the non-conducting state, thereby reducing generated electrical noise, and for supplying equivalent values of drive voltage to two motors of different power ratings which rotate respective cooling fans, to obtain equalized levels of air flow rate.

The present invention provides a system and methods for assaying nucleic acid molecules with reduced levels of background signal and enhanced specificity and sensitivity. In particular, the present invention provides a system and methods for detecting, sorting, tracking and characterizing nucleic acid molecules using hybridization assays with reduced levels of undesirable cross hybridization and reduced levels of intramolecular secondary structure.

Dialysis solutions with enhanced biocompatibility are provided. The dialysis solutions include a first acidic solution and a second acidic solution that are admixed to form a ready-to-use dialysis solution with reduced levels of glucose degradation products prior to use. The first acidic solution includes a dextrose concentrate, and the second acidic solution includes a buffer concentrate, such as a lactate-based buffer. The first and second acid solutions are separately sterilized prior to mixing to form the ready-to-use dialysis solutions. The dialysis solutions can be used in a variety of different applications, such as infusion into a patient during peritoneal dialysis.

A plasma processing apparatus performs a plasma processing on a substrate to be processed by generating plasma between a first electrode and a second electrode disposed to face each other in a processing chamber by applying a radio frequency power to the first electrode from a radio frequency power supply connected to the first electrode. The plasma processing apparatus includes a dielectric body disposed near the first electrode and a conductor provided in the dielectric body. Further, a radio frequency leakage line is connected to the conductor, and the radio frequency power applied to the first electrode leaks through the radio frequency leakage line to an earth ground. In addition, an impedance adjusting circuit is provided on the radio frequency leakage line and controls an amount of the radio frequency power flowing through the radio frequency leakage line by adjusting an impedance.

Novel structuring compositions and food products including those compositions are provided. The compositions comprise a mono- and diglyceride mixture and have high levels of β′ crystals and small average crystallite sizes. They can be incorporated into intermediate food products such as shortenings and margarines, which can then be used to make a final food such as pastries (e.g., puff pastries, Danishes, donuts), doughs (e.g., for cookies, pie crusts), imitation cheese, icings, frozen potatoes (e.g., French Fries), and / or other foods requiring a fat to provide structure. Advantageously, the compositions provide structure to the final food by replacing unhealthy fats that would otherwise be used to provide structure in the same food item.

A MEMS vapor bubble generator with a chamber for holding liquid and a heater positioned in the chamber for heating the liquid above its bubble nucleation point to form a vapour bubble; wherein, the heater is formed from a superalloy.

The present invention relates to methods of treating a subject diagnosed with autism or an autism spectrum disorder, lowering the level of mercury in a subject determined to contain a high level of mercury, methods of lowering the level of mercury in a child diagnosed with autism, lowering the level of at least one androgen in a subject diagnosed with autism, lowering the level of mercury and the level of at least one androgen in a subject diagnosed with autism and methods of assessing the risk of whether a child is susceptible of developing autism.

An apparatus and method for stimulating animal tissue (for example to trigger a nerve action potential (NAP) signal in a human patient) by application of both electrical and optical signals for treatment and diagnosis purposes. The application of an electrical signal before or simultaneously to the application of a NAP-triggering optical signal allows the use of a lower amount of optical power or energy than would otherwise be needed if an optical signal alone was used for the same purpose and effectiveness. The application of the electrical signal may precondition the nerve tissue such that a lower-power optical signal can be used to trigger the desired NAP, which otherwise would take a higher-power optical signal were the electric signal not applied. Some embodiments include an implanted nerve interface having a plurality of closely spaced electrodes placed transversely and / or longitudinally to the nerve and a plurality of optical emitters.

Described herein is a method for reducing levels of the harmful metabolic waste product of S-adenosylmethionine (SAMe), homocysteine, and provide vitamin and other nutritional co-factors that reduce the production of homocysteine and either re-methylate homocysteine back to S-adenosylmethionine, or facilitate its conversion downstream to cystathione. The method of the invention may be achieved by administering 5-methyl tetrahydrofolate, methylcobalamin, and one or more compounds selected from the group consisting of betaine, pyridoxal-5-phosphate, N-acetyl-cysteine, and other cofactors.

A method and system for controlling the temperature of recirculated exhaust gas in an exhaust gas recirculation (EGR) system, such as those used in connection with diesel engines. An EGR loop (which may be either a high pressure loop or a low pressure loop) has a dual-leg segment with an EGR cooler on one leg and an EGR heater on the other leg. By means of a valve, the EGR gas may be diverted to either one leg or the other, thereby providing either cooled or heated EGR gas to the engine.

Disclosed is a synthetic silica glass optical material having high resistance to optical damage by ultraviolet radiation in the ultraviolet wavelength range, particularly in the wavelength less than about 250 nm and particularly, exhibiting a low laser induced wavefront distortion; specifically a laser induced wavefront distortion, measured at 633 nm, of between about −1.0 and 1.0 nm / cm when subjected to 10 billion pulses of a laser operating at approximately 193 nm and at a fluence of approximately 70 μJ / cm2. The synthetic silica glass optical material of the present invention comprises OH concentration levels of less than about 600 ppm, preferably less than 200 ppm, and H2 concentration levels less than about 5.0×1017 molecules / cm3,and preferably less than about 2.0×1017 molecules / cm3.

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and / or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutic amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof:whereinZ1 is N or CR3;Z2 is N or CR4;Z3is O or S;A is hydrogen, alkyl or M+;M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc or a mixture thereof;R1, R2, R3 and R4 are independently selected from hydrogen, alkyl, hydroxy alkoxy, aryl, acyl, halo, cyano, haloalkyl, NHCOOR5 and SO2NH2;R5 is aryl, arylalkyl, heteroaryl or heteroarylalkyl;at least one of R1, R2, R3 and R4 is other than hydrogen; andat least one of Z1 and Z2 is other than N.

Methods for the treatment of insulin resistance, diabetes, and / or diabetes associated dyslipidemia by administering niacin and meloxicam are disclosed.

Dialysis solutions with enhanced biocompatibility are provided. The dialysis solutions include a first acidic solution and a second acidic solution that are admixed to form a ready-to-use dialysis solution with reduced levels of glucose degradation products prior to use. The first acidic solution includes a dextrose concentrate, and the second acidic solution includes a buffer concentrate, such as a lactate-based buffer. The first and second acid solutions are separately sterilized prior to mixing to form the ready-to-use dialysis solutions. The dialysis solutions can be used in a variety of different applications, such as infusion into a patient during peritoneal dialysis.

The present invention is directed to an assay for ADAMTS-13 activity. The assay provides rapid analysis of ADAMTS-13 activity in a biological sample under non-denaturing conditions. Furthermore, the present invention is directed to a recombinant polypeptide with a functional ADAMTS-13 site that is useful in ADAMTS-13 activity assays.

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials.